Biocellvia co-signs with Prof. Leclercq a scientific article about its own technology dedicated to NAFLD/NASH

EASL International Liver Congress
Biocellvia presented a poster at the International Liver Congress
juillet 24, 2019
Scientific publication with Prof. Diehl
Biocellvia co-signed a scientific article on a NASH breakthrough innovation with Prof. Diehl from Duke University
septembre 26, 2019
Show all

Biocellvia co-signs with Prof. Leclercq a scientific article about its own technology dedicated to NAFLD/NASH

Scientific publication with Prof. Leclercq

Prof. Yvon Julé, Biocellvia’s Chief Scientific Officer, co-signed a scientific publication with a prestigious research team from Belgium : the team directed by Prof. Isabelle Leclercq from University of Louvain in Laboratory Investigation. This article is entitled : “Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH“.

Digital and fully-automated quantification of NASH parameters

This publication demonstrates robustness and reliability of data produced by Biocellvia softwares. The abstract of the article concludes with these words : “The automated procedure also faithfully captured and quantitated macrovesicular steatosis, mixed inflammation, and pericellular fibrosis in CDAA-induced steatohepatitis. In conclusion, the automatic numerical analysis represents a promising quantitative method to rapidly monitor NAFLD activity with high-throughput in large preclinical studies and for accurate monitoring of disease evolution.”

Strong correlation between scoring and quantitative digital image analysis on NASH

This article is a strong reference for Biocellvia’s technology that evaluates quantitatively the efficacy of lead molecules for NAFLD/NASH on whole mice liver sections. Biocellvia quantifies on digital scans of liver sections three key parameters involved in Non Alcoholic Steato-Hepatitis (NASH) : steatosis, fibrosis and inflammation. This accuracy enables to evaluate those parameters with high reliability. Biocellvia enables “Big Pharma”, biotechs, CRO and academic research teams to get GO/ NO GO decisions thanks to robust data produced by its own algorithms. Biocellvia’s technology is protected by patent and commercialized as a service. Fully-automated quantitative digital image analysis can replace scoring performed by pathologists as we can read it in the abstract : “Automated measurement of steatosis (macrovesicular steatosis area) revealed a strong correlation with steatosis scores (r = 0.89), micro-CT liver density, liver lipid content (r = 0.89), and gene expression of CD36 (r = 0.87). Automatic assessment of the number of F4/80-immunolabelled crown-like structures strongly correlated with conventional inflammatory scores (r = 0.79). In Foz HF mice, collagen deposition, evident at week 20 and progressing at week 34, was automatically quantified on picrosirius red-stained entire liver sections.”

Link to the article :

I have a background as a researcher academic with more than 30 years of age experience. Professor at the "Mayo Clinic " (USA), I created the company Biocellvia in 2011 with my son Olivier Julé. During the creation of the box, I perceived the power of digital image analysis in the framework of the research, and the interest that they cause.

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

We are working hard on our new website!
Unfortunately, we haven't yet found a technology as fast as Biocellvia's .
Please be kind to our old design and come say hello to the new one when it is up and running.